Opioid use disorder in pregnancy: A strategy for using methadone

Divided doses can help address the unique needs of patients who are pregnant

In the United States, opioid use by patients who are pregnant more than quadrupled from 1999 to 2014. Opioid use disorder (OUD) in the perinatal period is associated with a higher risk for depression, suicide, malnutrition, domestic violence, and obstetric complications such as spontaneous abortion, preeclampsia, and premature delivery. Buprenorphine and methadone are the standard of care for treating OUD in pregnancy. While a literature review found that maternal treatment with buprenorphine has comparable efficacy to treatment with methadone, a small randomized, double-blind study found that compared to buprenorphine, methadone was associated with significantly lower use of additional opioids (P = .047). This suggests methadone has therapeutic value for patients who are pregnant.

Despite the benefits of methadone for treating perinatal OUD, the physiological changes that occur in patients who are pregnant—coupled with methadone’s unique pharmacologic properties—may complicate its use. Patients typically take methadone once a day, and the dose is titrated every 3 to 5 days to allow serum levels to reach steady state. During pregnancy, there are increases in both the volume of distribution and medication metabolism secondary to increased expression of the cytochrome P450 3A4 enzyme by the liver, intestine, and placenta. Additionally, as the pregnancy progresses, the rate of methadone metabolism increases. Methadone’s half-life (20 to 35 hours) leads to its accumulation in tissue and slow release into the blood. As a result, divided doses can help address the unique needs of patients who are pregnant.

Disclosures
The authors report no financial relationships with any companies whose products are mentioned in this article, or with manufacturers of competing products.

doi: 10.12788/cp.0427

Sitara Soundararajan, MD
PGY-3 Psychiatry Resident
Department of Psychiatry and Behavioral Sciences
Montefiore Medical Center
Bronx, New York

Kristine Torres-Lockhart, MD
Assistant Professor
Department of Medicine and Department of Psychiatry and Behavioral Sciences
Albert Einstein College of Medicine
Bronx, New York

Rubiahna Vaughn, MD, MPH
Assistant Professor
Department of Psychiatry and Behavioral Services
Albert Einstein College of Medicine
Director, Consultation-Liaison and Emergency Psychiatry
Department of Psychiatry and Behavioral Sciences
Montefiore Medical Center, Weiler Hospital
Bronx, New York

EMILIA KULIYEV/SHUTTERSTOCK
Opioid use disorder in pregnancy

CASE 1
Ms. H, age 29, is G3P2 and presents to the emergency department (ED) during her fourth pregnancy at 31 weeks, 1 day gestation. She has a history of opioid, cocaine, and benzodiazepine use disorders and chronic hepatitis C. Ms. H is enrolled in an opioid treatment program and takes methadone 190 mg/d in addition to nonprescribed opioids. In the ED, Ms. H requests medically supervised withdrawal management. Her urine toxicology is positive for cocaine, benzodiazepines, methadone, and opiates. Her laboratory results and electrocardiogram (ECG) are unremarkable. On admission, Ms. H’s Clinical Opiate Withdrawal Scale (COWS) score is 3, indicating minimal symptoms (5 to 12: mild; 13 to 24: moderate; 25 to 36: moderately severe; >36: severe). Fetal monitoring is reassuring. Ms. H’s withdrawal is monitored with COWS every 4 hours. The treatment team initiates methadone 170 mg/d, with an additional 10 mg/d as needed to keep her COWS score <8, and daily QTc monitoring. Ms. H also receives lorazepam 2 to 4 mg/d as needed for benzodiazepine withdrawal. Despite the increase in her daily methadone dose, Ms. H continues to experience opioid withdrawal in the early evening and overnight. As a result, the treatment team increases Ms. H’s morning methadone dose to 190 mg and schedules an afternoon dose of 30 mg. Despite this adjustment, her COWS scores remain elevated in the afternoon and evening, and she requires additional as-needed doses of methadone. Methadone peak and trough levels are ordered to assess for rapid metabolism. The serum trough level is 190 ng/mL, which is low, and a serum peak level is not reported. Despite titration, Ms. H has a self-directed premature discharge.

Five days later at 32 weeks, 2 days gestation, Ms. H is readmitted after she had resumed use of opioids, benzodiazepines, and cocaine. Her vital signs are stable, and her laboratory results and ECG are unremarkable. Fetal monitoring is reassuring. Given Ms. H’s low methadone serum trough level and overall concern for rapid methadone metabolism, the treatment team decides to divide dosing of methadone. Over 9 days, the team titrates methadone to 170 mg twice daily on the day of discharge, which resolves Ms. H’s withdrawal symptoms.

At 38 weeks, 5 days gestation, Ms. H returns to the ED after experiencing labor contractions and opiate withdrawal symptoms after she resumed use of heroin, cocaine, and benzodiazepines. During this admission, Ms. H’s methadone is increased to 180 mg twice daily with additional as-needed doses for ongoing withdrawal symptoms. At 39 weeks, 2 days gestation, Ms. H has a scheduled cesarean delivery.

Her infant has a normal weight but is transferred to the neonatal intensive care unit (NICU) for management of neonatal opioid withdrawal syndrome (NOWS) and receives morphine. The baby remains in the NICU for 35 days and is discharged home without further treatment. When Ms. H is discharged, her methadone dose is 170 mg twice daily, which resolves her opioid withdrawal symptoms. The treatment team directs her to continue care in her methadone outpatient program and receive treatment for her cocaine and benzodiazepine use disorders. She declines residential or inpatient substance use treatment.

CASE 2
Ms. M, age 39, is G4P2 and presents to the hospital during her fifth pregnancy at 27 weeks gestation. She has not received prenatal care for this pregnancy. She has a history of OUD and major depressive disorder (MDD). Ms. M’s urine toxicology is positive for opiates, fentanyl, and oxycodone. Her laboratory results are notable for mildly elevated alanine aminotransferase, positive hepatitis C antibody, and a hepatitis C viral load of 91,000, consistent with chronic hepatitis C infection. On admission, her COWS score is...
14, indicating moderate withdrawal symptoms. Her ECG is unremarkable, and fetal monitoring is reassuring.

Ms. M had received methadone during a prior pregnancy and opts to reinitiate treatment with methadone during her current admission. The team initiates methadone 20 mg/d with additional as-needed doses for ongoing withdrawal symptoms. Due to a persistently elevated COWS score, Ms. M’s methadone is increased to 90 mg/d, which resolves her withdrawal symptoms. However, on Day 4, Ms. M reports having anxiety, refuses bloodwork to obtain methadone peak and trough levels, and prematurely discharges from the hospital.

One day later at 27 weeks, 5 days gestation, Ms. M is readmitted for continued management of opioid withdrawal. She presents with stable vital signs, an unremarkable ECG, and reassuring fetal monitoring. Her COWS score is 5. The treatment team reinitiates methadone at 80 mg/d and titrates it to 100 mg/d on Day 7. Given Ms. M’s ongoing evening cravings and concern for rapid methadone metabolism, on Day 10 the team switches the methadone dosing to 50 mg twice daily to maintain steady-state levels and promote patient comfort. Fluoxetine 20 mg/d is started for comorbid MDD and eventually increased to 80 mg/d. Ms. M is discharged on Day 15 with a regimen of methadone 60 mg/d in the morning and 70 mg/d at night. She plans to resume care in an opioid treatment program and follow up with psychiatry and hepatology for her anxiety and hepatitis C.

### A need for aggressive treatment

Given the rising rates of opioid use by patients who are pregnant, harmful behavior related to opioid use, and a wealth of

### Table

**Recommendations for methadone treatment of opioid use disorder in patients who are pregnant**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Recommendation(s)</th>
</tr>
</thead>
</table>
| Starting dose           | • If the patient is already receiving methadone, continue the baseline outpatient dose  
• If the patient is not receiving methadone, the starting dose should be 20 to 30 mg/d based on the risk of CNS and respiratory depression and the presence of comorbidities  
• Monitor withdrawal symptoms by administering COWS every 4 to 6 h |
| Dose increase           | • Increase dose by 5 to 20 mg/d for ongoing withdrawal symptoms  
• Increase dose every 3 to 5 d to reach steady-state metabolism; faster titrations are possible in hospital settings with close monitoring  
• Consider divided dosing if there is concern for rapid metabolism |
| Laboratory testing      | • Obtain methadone peak and trough levels at baseline if you suspect rapid metabolism while adjusting dose |
| Patient safety monitoring | • Conduct serial vital signs of the mother  
• Monitor for respiratory depression and sedation  
• Conduct daily ECGs to monitor QTc interval if there is concern for QT prolongation, structural heart disease, other QTc-prolonging medications, or if the patient is receiving methadone ≥100 mg total daily dose  
• Monitor for ongoing withdrawal symptoms, cravings, and nonprescribed opioid use  
• Consider dose decrease and dose consolidation in the peripartum period as the physiological changes of pregnancy subside |
| Fetal monitoring        | • Conduct fetal heart monitoring, nonstress testing, and biophysical profiles as needed |
| Other considerations    | • Provide patient-centered, nonjudgmental, trauma-informed care and adequate pain management to decrease the risk of premature self-directed discharge  
• Emphasize harm reduction and overdose prevention  
• Collaborate with an interdisciplinary team of addiction medicine, obstetrics, psychiatry, and social work clinicians to improve outcomes |

COWS: Clinical Opiate Withdrawal Scale; ECG: electrocardiogram

### Clinical Point

Patient-centered, nonjudgmental, trauma-informed care and adequate pain management can reduce the risk of premature discharge
Evidence supporting opioid agonist treatment for OUD in pregnancy, there is a growing need for guidance in managing perinatal OUD. A systematic approach to using methadone to treat OUD in patients who are pregnant is essential; the lack of data surrounding use of this medication in such patients may cause overall harm. Limited guidelines and a lack of familiarity with prescribing methadone to patients who are pregnant may lead clinicians to underdose patients, which can result in ongoing withdrawal, premature patient-directed discharges, and poor engagement in care. Both patients in the 2 cases described in this article experienced ongoing withdrawal symptoms despite daily titration of methadone. This suggests rapid metabolism, which was successfully managed by dividing the dosing of methadone, particularly in the latter trimesters.

These cases illustrate the need for aggressive perinatal opioid withdrawal management through rapid escalation of divided doses of methadone in a monitored acute care setting. Because methadone elimination is more rapid and clearance rates increase during the perinatal period, divided methadone dosing allows for sustained plasma methadone concentrations and improved outpatient treatment adherence.\(^9,14,15\)

**Decreasing the rate of premature discharges**

In both cases, the patients discharged from the hospital prematurely, likely related to incomplete management of their opioid withdrawal or other withdrawal syndromes (both patients had multiple substance use disorders [SUDs]). Compared to patients without an SUD, patients with SUDs are 3 times more likely to have a self-directed discharge.\(^{16}\) Patients report leaving the hospital prematurely due to undertreated withdrawal, uncontrolled pain, discrimination by staff, and hospital restrictions.\(^{16}\) Recommendations to decrease the rates of premature patient-directed discharges in this population include providing patient-centered and harm reduction–oriented care in addition to adequate management of pain and withdrawal.\(^{17}\)

**Impact of methadone on fetal outcomes**

Approximately 55% to 94% of infants born to patients who are opioid-dependent will develop NOWS. However, there is no relationship between this syndrome and therapeutically therapeutic doses of methadone.\(^{18}\) Moreover, long-term research has found that after adjusting for socioeconomic factors, methadone treatment during pregnancy does not have an adverse effect on postnatal development. Divided dosing in maternal

**Related Resources**


**Drug Brand Names**

- Buprenorphine • Buprenex, Suboxone, Zubsolv, Sublocade
- Fentanyl • Abstral, Actiq
- Fluoxetine • Prozac
- Lorazepam • Ativan
- Methadone • Methadose, Dolophine
- Oxycodone • Oxycontin
methadone administration is also shown to have less of an impact on fetal neurobehavior and NOWS.19

Our recommendations for methadone treatment for perinatal patients are outlined in the Table (page e13). Aggressive treatment of opioid withdrawal in the hospital can promote treatment engagement and prevent premature discharges. Clinicians should assess for other withdrawal syndromes when a patient has multiple SUDs and collaborate with an interdisciplinary team to improve patient outcomes.

References
10. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol Series No. 43. Substance Abuse and Mental Health Service Administration; 2005.